The Venture Codex Logo

The Venture Codex

Bio4Dreams

Viale Decumano 41, Palazzina Cocoon – Entrance 8, Milano, Lombardia, 20157, Italy

Overview

Bio4Dreams is a fully privately funded certified incubator, accelerator, and company builder, established in 2017 and entirely dedicated to very early-stage innovative startups in the Life Sciences sector. We support exceptional individuals in turning their scientific research results into tangible business opportunities, working alongside all stakeholders in the innovation chain to build sustainable, pragmatic, and long-lasting ventures with an international outlook. Our distinctive strength lies in our ability to think outside the box. We aim to foster a broad international innovation ecosystem in Life Sciences, positioning Bio4Dreams as a reference point and beacon for entrepreneurial ideas. We go far beyond the traditional definition of a startup incubator: we accompany each project along its entire development journey, starting from its earliest stages. Moreover, we do not limit ourselves to simple collaborations with key innovation players — we actively work to integrate them into a wider, synergistic ecosystem. The key strengths of Bio4Dreams include fully customized and flexible incubation and acceleration programs, developed through shared and validated methodologies, combined with a strong international orientation that allows startups to immediately compete on a global scale.

Total investments
1
Lead investments
0
Investments · 12mo
1
Active investors
9

Sector focus

  • Biopharma
  • Biotechnology
  • Health Care
  • Health Diagnostics
  • Life Science
  • Medical
  • Medical Device
Visit website

Investment portfolio

  • ChemiCare

    Participated · Seed · Dec 2025

    ChemiCare is a life-sciences spin-off from the Università degli Studi del Piemonte Orientale focused on discovering and developing therapies for severe neuromuscular and autoimmune disorders. Its lead program is CIC-39, a small-molecule candidate aimed at treating Duchenne Muscular Dystrophy as well as a range of autoimmune pathologies. The company’s stated objective is to advance CIC-39 into first-in-human clinical trials within the next 18 months. By translating academic research into clinically actionable therapies, ChemiCare seeks to deliver high-impact solutions for patients who currently have limited treatment options. The business model leverages close collaboration with academic labs while tapping external venture and public funds to finance development. The recent €2.5 million seed infusion provides the initial capital needed for pre-clinical work, regulatory preparation, and early manufacturing activities. No revenue, user, or previous funding metrics were disclosed in the article.

Team

  • Pietro Conti

    CEO

  • Laura Iris Ferro

    President

    LinkedIn
  • Elisabetta Borello

    Co-founder, VP Strategy and External Relations

  • Demetra Pelos

    Strategic Project Director & Head of Business Nursery